PEPTIDE CORTEXThe library
← The library

CJC-1295 with DAC

researchGH Axis
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeGH axis
MechanismGHRH analog bound to a Drug Affinity Complex, extending half-life to roughly a week versus hours for the unmodified peptide
EffectsSignals the GH axis continuously rather than in pulses, which is a meaningfully different exposure profile from the no-DAC form
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published2 sourced
Clinical trialSingle-dose study in healthy adults (Teichman, JCEM 2006)
RouteSubcutaneous
FrequencySingle dose
StartingSingle SC doses of 30, 60 or 125 mcg/kg
EscalationNone
TargetNot a therapeutic regimen. 60 mcg/kg gave about 2-fold GH elevation for 6 days; best tolerated at 30 or 60 mcg/kg.

Half-life 5.8-8.1 days.

Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous
FrequencyOnce weekly (or split twice weekly)
Starting500-1,000 mcg once weekly, weeks 1-2
EscalationTo 1,000 mcg/week weeks 3-8; "elevated" 2,000 mcg/week or 1 mg twice weekly, weeks 3-12
Target1,000 mcg (1 mg) once weekly ("most common maintenance dose")
CycleStandard 8-12 weeks on / 4-6 weeks off; extended 12-16 weeks on / 6-8 weeks off
Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Not FDA-approved; avoid self-administration; unverified sourcing and purity

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.